Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
Do you have a maximal limit to the number of pegylated doxorubicin cycles you will prescribe a patient for recurrent endometrial cancer?
Related Questions
For a borderline ovarian tumor that has been resected with BSO and hysterectomy, would you consider endocrine therapy if found to be ER-positive?
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
What are your top takeaways from SGO 2025?
How would you manage a patient with FIGO stage IIIB endometrial carcinoma who developed significant back pain with Carboplatin/Paclitaxel cycle 1, which worsened during cycle 2?
What does bevacizumab contribute in metastatic cervical cancer when used in combination with a platinum doublet + pembrolizumab?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
Would you offer systemic chemotherapy to a patient with at least 2023 FIGO stage IC high grade serous (p53-mut) endometrial cancer with extensive LVI for whom nodal assessment was not done?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
